Clinical Scorecard: The Worldwide Clinical Trial Landscape for PD-1-Targeting Bispecific Antibodies in Gastric Cancer: Current Insights and Future Strategies for Overcoming Immune Tolerance

At a Glance

Key Highlights

• 121 interventional clinical trials identified as of April 17, 2026.
• Phase II trials represent the largest segment of the developmental pipeline.
• Combination therapy with chemotherapy is the predominant strategy.
• CTLA-4 is the most common non-PD-1 co-target.
• Majority of trials conducted in China.

Guideline-Based Recommendations

Diagnosis

• Histologically confirmed gastric cancer is required for trial eligibility.

Management

• PD-1-containing bispecific antibodies should be considered to enhance antitumor immunity.

Monitoring & Follow-up

• Safety profiles and preliminary anti-tumor efficacy should be evaluated in ongoing trials.

Risks

• Therapeutic resistance and immune tolerance remain significant challenges.

Patient & Prescribing Data

Patients with advanced gastric cancer, particularly those in stage III/IV.

Combination therapies are more common in trials led by Chinese institutions.

Clinical Best Practices

• Focus on biomarker-driven patient stratification.
• Prioritize combination strategies to target immune tolerance.

Related Resources & Content

• INFORMA Database